Matinas BioPharma Inc.

MTNB | AMEX

Price Alert Chart Builder DCF Calculator

$1.30

-$0.21 (-13.91%)

Nov 2, 2026, 12:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-13.91%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

22.5

+3.0 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #966/1028 (Top 94%)

Full Analysis

Key Statistics

Market Data

Market Cap $555.2K

1D Range

0.98 1.51

52W Range

0.97 20.10

Valuation (TTM)

PE -0.08

PB 0.36

EV/EBITDA 0.02

Valuation (NTM)

Forward PE N/A

Forward PEG -0.00

Price Target $0.00

Cash Flow

FCF Yield -995.5%

SBC Adj. FCF Yield -1084.5%

SBC Impact -8.9%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | -62.4%

Dil EPS 3Y | 5Y 56.9% | 20.0%

FCF 3Y | 5Y 48.7% | 23.0%

Returns

ROA -214.2%

ROE -181.4%

ROIC -323.2%

Financial Health

Net Cash

$761K

Current Ratio 0.85

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovati...

Sector Healthcare

Industry Biotechnology

Employees 2

IPO Date Jul 21, 2014

Website www.matinasbiopharma.com

Fiscal Year January - December

Full Company Profile

Latest News

2 months ago · globenewswire.com

GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output

Agreement establishes GH Power's first commercial hydrogen offtake and validates hydrogen production from the Company's proprietary aluminum-water reactor platform Agreement establishes GH Power's first commercial hydrogen offtake and validates hydrogen production from the Company's proprietary aluminum-water reactor platform

2 months ago · globenewswire.com

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years.

4 months ago · globenewswire.com

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞